Novel therapies with multi-modal effects for treatment of neurodegenerative conditions

NeuroBo Pharmaceuticals has a phase 3-ready drug candidate, NB-01, in development for painful diabetic neuropathy and a number of other indications, as well as an investigational new drug (IND)-ready candidate, NB-02, that targets Alzheimer’s disease and tauopathies.

Like Comment
Page of
Go to the profile of NeuroBo Pharmaceuaticals

NeuroBo Pharmaceuaticals

NeuroBo Pharmaceuticals is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. Their first product candidate, NB-01, is targeting neuropathic pain with a first indication in PDN. Phase 3 studies are planned and powered for efficacy and safety. Diabetes and cancer are amongst the leading causes of neuropathic pain. PDN affects 8.4M people worldwide representing global drug sales of $3.05B (2018, GlobalData) Current treatments show limited reduction of pain in half of patients

No comments yet.